Tag Archives: commercialization

Ashfield Launches EmerGENE to Support Biotechs’ Commercialization Activities

Ashfield, part of UDG Healthcare plc, has announced the launch of EmerGENE, a global end-to-end cell and gene therapy network approach which promises to support small and midsize biotechs with the commercialization of their discoveries

EVERSANA Partners With Resverlogix to Commercialize Breakthrough Cardiovascular/CKD drug

In preparation for launch, Resverlogix will utilize EVERSANA’s fully integrated commercialization services

NUZYRA Continues to be the Primary Driver for Paratek Pharmaceuticals’ Growth

The FDA approved Paratek’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA® for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP)

Avista Capital Partners Prepares to Divest United BioSource

Avista Capital Partners (Avista) is preparing to sell United BioSource Corporation (UBC), PE Hub reported. Avista acquired UBC in 2017 from Express Scripts. UBC, founded in 2003, is a market leader in providing integrated, comprehensive clinical, safety, and commercialization services. UBC brings together renowned scientific research and operations experts with leading-edge technologies, allowing for the best patient and […]

SCYNEXIS Partnering with Amplity Health to Launch BrexafemmeTM

SCYNEXIS announced that it has partnered with Amplity Health, a leading global contract commercialization organization, to support the anticipated U.S. commercialization of Brexafemme

Amplity Health Growing its Commercialization Business with SCYNEXIS Agreement

Amplity Health offers commercial execution expertise and resources for sales force, remote engagement, training, market access and select operations services

CareMetx’s Private Equity Investments to Accelerate Company’s Growth

Recently, CareMetx started a new division, OutcomeRx, to focus on holistic solutions for  biotech companies to address the patient, manufacturer, and payer challenges in the evolving Cell and Gene Therapy (CGT) market

BluePrint’s AYVAKIT and GAVRETO™ Selected Biologics and PantherRx Rare as Limited Specialty Pharmacies

Blueprint creates medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease